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Among 1614 children with acute lympho-
blastic leukemia (ALL) treated with the
Nordic Society for Paediatric Haematol-
ogy and Oncology (NOPHO) ALL-92 proto-
col, 20 patients developed a second malig-
nant neoplasm (SMN) with a cumulative
risk of 1.6% at 12 years from the diagno-
sis of ALL. Nine of the 16 acute myeloid
leukemias or myelodysplastic syndromes
had monosomy 7 (n  7) or 7q deletions
(n  2). In Cox multivariate analysis,
longer duration of oral 6-mercaptopurine
(6MP)/methotrexate (MTX) maintenance
therapy (P  .02; longest for standard-
risk patients) and presence of high hy-
perdiploidy (P  .07) were related to
increased risk of SMN. Thiopurine methyl-
transferase (TPMT) methylates 6MP and
its metabolites, and thus reduces cellular
levels of cytotoxic 6-thioguanine nucleo-
tides. Of 524 patients who had erythro-
cyte TPMT activity measured, the median
TPMT activity in 9 patients developing an
SMN was significantly lower than in the
515 that did not develop an SMN (median,
12.1 vs 18.1 IU/mL; P  .02). Among
427 TPMT wild-type patients for whom the
6MP dose was registered, those who de-
veloped SMN received higher average
6MP doses than the remaining patients
(69.7 vs 60.4 mg/m2; P  .03). This study
indicates that the duration and intensity
of 6MP/MTX maintenance therapy of child-
hood ALL may influence the risk of SMNs
in childhood ALL. (Blood. 2009;113:
6077-6084)
Introduction
A few percent of children with acute lymphoblastic leukemia
(ALL) will develop a second malignant neoplasm (SMN), and this
complication has a poor prognosis.1-5 Treatment-related risk factor
analyses have focused primarily on irradiation, alkylating agents,
and topoisomerase II inhibitors such as anthracyclines and epipodo-
phyllotoxins that can induce DNA damage, whereas less attention
has been paid to mechanisms that could interfere with DNA
control, including drugs that may modify DNA repair.5
Previously, children with higher risk ALL had a higher risk of
SMNs because of their more intensive chemotherapy, radio-
therapy, or both.6 However, a few studies have indicated that the
less intensive 6-mercaptopurine (6MP)/methotrexate (MTX)
maintenance therapy also enhances the risk of SMNs. The
Nordic Society for Paediatric Haematology and Oncology
(NOPHO) ALL-92 6MP/MTX maintenance therapy trial re-
ported 3 cases of acute myeloid leukemia or myelodysplastic
syndrome (t-AML/MDS) among 55 children, who had thiopu-
rine methyltransferase (TPMT) activity compatible with TPMT
low-activity polymorphisms (cumulative risk, 9%), compared
with only 2 cases among 384 patients (cumulative risk, 1%)
with normal TPMT activity.7 Similarly, St Jude Children’s
Research Hospital has reported that children with ALL who
were heterozygous for TPMT low-activity polymorphisms had
an excessive risk of SMNs if exposed to cranial irradiation.8
Low-activity TPMT polymorphisms lead to higher intracellular
levels of 6-thioguanine nucleotides (6TGN), which are the
cytotoxic 6MP metabolites that are incorporated into DNA.9,10
In addition, some of the methylated 6MP metabolites formed by
TPMT are strong inhibitors of purine de novo synthesis,11 and,
because their levels increase with higher doses of 6MP,12 such
6MP dose increments in TPMT high-activity patients may lead
to enhanced DNA-6TGN incorporation even in patients without
TPMT low-activity polymorphisms.
To explore further the possible effect of 6MP/MTX mainte-
nance therapy on the risk of SMNs, we reviewed the cumulative
incidence of SMNs among the total cohort of 1614 patients treated
according to the NOPHO ALL-92 protocol and report that the risk
of SMNs in patients treated on this protocol correlates with TPMT
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activity or the dose intensity of oral 6MP/MTX maintenance
therapy or both.
Methods
Patients
From January 1992 until October 2001, 1703 children 1.0 to 14.9 years of
age were diagnosed with B-cell precursor or T-cell ALL in the Nordic
countries (Denmark, Finland, Iceland, Norway, and Sweden; Figure 1). Two
patients with Down syndrome received no antileukemic therapy, 10 patients
were treated according to non-NOPHO ALL protocols, 1 patient was
treated according to the previous NOPHO ALL-86 protocol, and 45 patients
were treated according to the NOPHO ALL-2000 protocol, before it was
officially opened. None of these 58 patients have developed an SMN during
their first complete remission (CR1). Of the remaining 1645 patients who
started therapy according to the NOPHO ALL-92 protocol, 22 patients died
during induction therapy, and 9 patients had resistant disease and were
excluded from further analysis. The remaining 875 boys and 739 girls were
included in the present study. Twenty-nine of these 1614 patients had Down
syndrome. The data used in this publication were retrieved from the
NOPHO Leukemia Registry. This registration has been approved by the
relevant ethical committees and the data protection agencies in the involved
countries. Informed consent was obtained in accordance with the Declara-
tion of Helsinki.
Risk grouping
The risk group criteria are given in Table 1.13 The patients who had higher
risk features at diagnosis and were assigned to the very high risk (VHR)
treatment arm received prophylactic or therapeutic central nervous system
(CNS) irradiation as well as LSA2L2 instead of MTX/6MP maintenance
therapy.
Treatment
For 55 of the 1614 patients, the assigned treatment did not completely
match the risk group criteria. Thirty-five patients with morphologically
No therapy
N=2
Other than ALL-92 protocol
N=56
Induction death
N=22
Resistant disease
N=9
SCT
N=52
3 developed SMN
Remission
N=436
TPMT: 391
CR1-death
N=3
TPMT:  3
Relapse
N=89
TPMT:  82
SMN
N=17
TPMT: 13
MTX/6MP data available
N=545
Remission
N=761
TPMT:  103
CR1 deaths
N=25
TPMT: 2
Relapse
N=231
TPMT: 15
SMN
N=0
TPMT: 0
Remainder
N=1017
No SCT
N=1562
Study population
N=1614
N=1645
1/1992-10/2001
N=1703 in Nordic countries
Figure 1. Flow chart of patient inclusion or exclusion.
Patients (n  545) participated in the randomized MTX/
6MP maintenance therapy study16 or they developed
SMNs and had their data on maintenance therapy 6MP/
MTX dosage and blood counts retrieved. Data on both
6MP/MTX doses and blood counts were not available for
all the 545 patients. TPMT phenotyping (n  524) or
genotyping or both were available for 609 patients.
Table 1. Risk group, therapy, and second malignant neoplasms in NOPHO ALL-92 protocol
SR-ALL
(n  562)*
IR-ALL
(n  590)†
HR-ALL
(n  239)‡
VHR-ALL
(n  223)§
Doxorubicin/daunomycin 120 240 280 400
Cyclophosphamide 0 3.000 3.000 6.600
Cranial irradiation No No No Yes
6MP/MTX (weeks) 117 72 41 0-8
Dead in CR1/relapse/SMN¶ 7/85/12 9/106/4 8/80/2 10/64/2
pEFS/pOS¶ 0.81/0.90 0.79/0.90 0.62/0.74 0.66/0.74
AML/MDS/solid tumor 5/7/0 1/1/2 2#/0/0 0/0/2#¶
12-year pSMN, mean  SE (%)** 2.4  0.7 1.2  0.7 1.2  0.8 1.1  0.8
AML indicates acute myeloid leukemia; CNS, central nervous system; dead in CR1, dead in first remission; M2/3 BM, greater than 5%/25% leukemic blasts in bone
marrow; MDS, myelodysplastic syndrome; 6MP/MTX, duration of oral 6MP/MTX maintenance therapy in weeks; pEFS/pOS, the 12-year probability of event-free survival and
overall survival, respectively; SNM, second malignant neoplasm; SR/IR/HR/VHR, standard/intermediate/high/very high risk of acute lymphoblastic leukemia; and WBC, white
blood cell.
*Risk criteria were age of 2.0 to 9.9 years, WBC count less than 10  109/L, and no HR/VHR criteria.
†Risk criteria were age of 1.0 to 1.9 year (or older than 10.0 years) or WBC count of 10 to 49  109/L, and no HR/VHR criteria.
‡Risk criteria were WBC count at least 50  109/L; T-cell, mediastinal, CNS, testicular, or lymphomatous disease; t(4;11) or t(9;22); M3 d15 or M2/3 d29; and no VHR
criteria.
§Risk criteria were HR-ALL at diagnosis and at least 5 years of age and (1) CNS leukemia, or (2) lymphomatous leukemia, or (3) d15 M3 or a d29 M2/3 BM, or (4) T-ALL with
1 or more other HR features.
Cumulative dose in mg/m2.
¶Twelve-year probability of event-free survival and overall survival.
#Three of the 4 SMNs occurred after stem cell transplantation in first remission.
**Twelve-year probability of developing an SMN.
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suspected, but uncertain, M3 bone marrow on day 15 or M2 bone marrow
on day 29 or both had standard risk (SR)–ALL (n  20) or intermediate risk
(IR)–ALL (n  15) by all other criteria and were treated according to the
SR or IR treatment arms, respectively. Two patients who fulfilled the
protocol criteria for SR-ALL or IR-ALL were by decision of the treating
physician assigned to the VHR-arm because of a t(1;19)(q23;p13) transloca-
tion (n  1) or hypodiploidy (n  1; modal number 35-36). Three patients
who fulfilled the VHR-ALL criteria were by decision of the treating
physician assigned to the high-risk (HR) arm. Furthermore, 9 patients who
fulfilled the SR-ALL criteria were by decision of the treating physician
assigned to the IR arm, and 6 patients who fulfilled the IR-ALL criteria
were likewise assigned to the SR arm. None of those 55 patients have
developed an SMN, and all were analyzed according to the therapy they
actually received.
Induction therapy and consolidation therapy. These therapies have
previously been published in detail.13 In short, all patients received
prednisolone (60 mg/m2 per day on days 1-36, then tapered), weekly
vincristine (VCR; 2.0 mg/m2 times 6), doxorubicin (40 mg/m2 times 3 [SR
and IR] or 4 [HR and VHR]), Erwinia asparaginase (30.000 IU/m2 daily on
days 37-46), and intrathecal MTX on 4 occasions. Subsequently and before
MT, SR-ALL patients received 3 courses of high-dose MTX (HD-MTX;
5 g/m2 every 24 hours with intrathecal MTX and leucovorin rescue),
whereas patients with IR-, HR-, and VHR-ALL received alternating
combination therapy blocks.
CNS irradiation and stem cell transplantation. Because of CNS
disease at diagnosis or allocation to the VHR protocol arm, 123 patients
who did not receive a transplant (7.6% of the total study population)
received cranial irradiation in CR1. Thirty-one boys and 21 girls with
higher-risk criteria received a stem cell transplant (SCT) in CR1, but no
uniform NOPHO indications for SC transplantation or for conditioning
therapy existed during the protocol period.14
Oral 6MP/MTX maintenance therapy. Maintenance therapy was
initiated for a total of 1317 patients at treatment week 13 (SR), 32 (IR), or
63 (HR) and scheduled to continue until 2 years (IR and HR) or 2.5 years
(SR) after diagnosis. However, for 32 patients the total duration of therapy
(and thus also the maintenance therapy phase) was by decision of the
treating physician prolonged for more than 12 weeks beyond that of the
protocol (median, 15 weeks). For a total of 85 patients, the precise dates for
the initiation (n  60) or cessation (n  17) of MTX/6MP maintenance
therapy or for both (n  8) were missing from the NOPHO leukemia
registry. For those 85 patients, the date for start of MTX/6MP maintenance
therapy was estimated from the median number of days from diagnosis for
the patients in that risk group for whom the dates were available (SR,
103 days; IR, 245 days; HR, 489 days), whereas the date for cessation of
maintenance therapy was set to be 2.0 years (IR- and HR-ALL) or 2.5 years
(SR-ALL) from diagnosis. None of those 85 patients developed SMN
during CR1. The starting doses of 6MP and MTX were 75 mg/m2 per day
and 20 mg/m2 per week, respectively. During the first year of maintenance
therapy, patients with SR- or IR-ALL received alternate pulses at 4-week
intervals of (1) VCR (2.0 mg/m2 once) and prednisolone (60 mg/m2 per day
for 1 week) and (2) HD-MTX (5 g/m2 every 24 hours with intrathecal MTX
and leucovorin rescue) until 5 courses of HD-MTX had been given.15 Every
8 weeks throughout maintenance therapy, HR patients received reinduc-
tions of VCR (1.5 mg/m2 once) and prednisolone (40 mg/m2 per day for
5 days) with intrathecal MTX. Between 1992 and 1996, 538 patients with
SR-, IR-, or HR-ALL were included in the randomized ALL-92 mainte-
nance therapy trial.16 It explored the prognostic effect of dose adjustments
of oral 6MP/MTX maintenance therapy by erythrocyte levels of 6MP/MTX
metabolites. TPMT genotype, phenotype, or both were not included in the
dose adjustments of that study. As part of that study nearly 30 000 datasets
on MTX and 6MP doses as well as parameters for myelotoxicity and
hepatotoxicity were registered and used in the present study for compari-
sons between patients who did or did not develop SMNs. For the purpose of
the present study, we also collected data on MTX and 6MP dosing and on
leukocyte and absolute neutrophil counts during maintenance therapy for
the patients with SMNs who were not included in the randomized study.
LSA2L2 maintenance therapy. On the basis of the unsatisfactory
results of the NOPHO ALL-86 protocol for patients with higher risk
ALL,13,17 NOPHO tested in a nonrandomized study the efficacy of
multidrug, cyclic LSA2L2 remission maintenance therapy to VHR-patients
(all Nordic countries) and to all Finnish patients with HR-ALL. LSA2L2
maintenance therapy was scheduled to be given from protocol weeks 48 to
95.13 However, antileukemic treatment was discontinued at week 104, even
if less than 6 LSA2L2 cycles had been due to treatment delays. If a patient
were able to complete 6 LSA2L2 maintenance therapy cycles before
treatment week 104, up to 9 weeks of oral MTX/6MP maintenance therapy
was given until week 104. Each LSA2L2 block consisted of 4 courses at
2-week intervals with alternating combinations of (1) 6-thiogunanine,
intravenous cyclophosphamide, and intrathecal MTX, (2) hydroxyurea and
daunorubicin (substituted with prednisolone/VCR after the first 4 hydroxy-
urea/daunorubicin cycles), (3) oral MTX and BCNU (1,3-bis(2-chloroethyl)-
1-nitrosourea), and (4) intravenous cytarabine and VCR.13,18-20
TPMT. The TPMT genotype (low-activity polymorphisms G460A and
A719G) or erythrocyte TPMT activity or both were available for 609 pa-
tients.21 For 484 of those patients only the erythrocyte TPMT activity was
available, and it was measured 1 to 5 times during maintenance therapy as
previously described.22 For patients with more than one TPMT activity
measurement, an arithmetic mean TPMT activity was calculated. All TPMT
phenotype assays were performed at least 8 weeks after the most recent
blood transfusion. The antimode of the TPMT activity distribution was
14 IU/mL. The 62 patients below that level, and for whom no TPMT
genotype was available, were classified as TPMT presumed heterozygous
(n  60; median TPMT-activity, 10.4 IU/mL; range, 6.2-13.9 IU/mL) or
TPMT-deficient (n  2; activity  1.0 IU/mL). Among the 40 patients for
whom both TPMT genotyping and phenotyping were available, all 9 pa-
tients who were TPMT heterozygous by genotyping had TPMT activity less
than 14.0 IU/mL. However, also 5 (16%) of 31 patients who had a
wild-type genotype had TPMT activity less than 14 IU/mL (range,
9.0-13.4 IU/mL), but they were classified by their genotype results as
TPMT wild-type. In total, 533 patients were classified as TPMT wild-type,
74 as heterozygous, and 2 as TPMT deficient. In the following analyses the
latter 2 subsets were grouped together as TPMT low activity, which
included the presumed heterozygous patients (TPMT activity  14 IU/mL;
no genotype available), and the remainder as TPMT wild-type. The TPMT
phenotype and genotype were not revealed to the physicians while the
patients were on therapy.
Karyotype. Only conventional G-band karyotyping was mandatory. In
addition, many patients were explored with high-resolution comparative
genomic hybridization, fluorescent in situ hybridization, or reverse
transcriptase–polymerase chain reaction for selected translocations [eg,
t(9;22)(q34;q11)].23 The karyotypes of the patients were described accord-
ing to ISCN (International System for Human Cytogenetic Nomenclature)
1995.24 For 664 patients, information on karyotypes was missing, or only
normal metaphases were obtained. Of the 950 aberrant karyotypes, 166 had
t(12;21)(p13;q22), 362 patients were classified as high-hyperdiploid with a
modal chromosome number of 51 to 60 chromosomes, 18 had t(1;19)(q23;
p13), 27 had t(9;22)(q34;q11), 11 had MLL rearrangements, 19 had a
hypodiploid karyotype (chromosome modal number  45, including one
case with t(9;22)[BCR/ABL]), and 348 cases had other chromosomal
aberrations.
Statistics
All patients were analyzed according to the treatment they actually
received. The duration of 6MP/MTX maintenance therapy was calculated
as the number of weeks between the initiation of 6MP/MTX maintenance
therapy and performance of a stem cell transplantation in CR1 (n  1), the
occurrence of an event, or the end of antileukemic therapy, whichever came
first. The average doses of 6MP and MTX were calculated as the total
prescribed doses divided by the duration of maintenance therapy. The risk
of SMN was calculated from the time of diagnosis, and survival analyses
were performed with a basic time scale defined by the date of diagnosis.
Patients who died in CR1, received a SCT in CR1, or developed a relapse
were censored at the time of these events in the analysis of SMN risk
factors. Cox proportional hazard regression analyses were performed with
the likelihood ratio test for differences in risk of SMN.25,26 Wilcoxon rank
sum test was applied to compare the distribution of parameters between
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subgroups.27 The Kaplan-Meier method was applied to estimate remission
duration and to generate survival curves.28 Subgroups were compared with
the log-rank test.29 Two-sided P values less than .05 were regarded as
significant.
Results
The median follow-up time for the 1225 patients who remain in
first remission is 10.4 years (50% range, 8.0-12.6 years). At the end
of the study, 34 patients had died in CR1, 335 patients had
developed a relapse of ALL 0.2 to 12.0 years from diagnosis
(median, 2.6 years), and 20 patients had developed an SMN
(Figure 1). The overall projected 12-year event-free survival and
overall survival were 75% ( 1%) and 86% ( 1%), respectively.
The 20 SMNs, including 3 that occurred after SC transplanta-
tion, were diagnosed at a median of 3.4 years (range, 0.8-
11.6 years) from the initial diagnosis of ALL (Table 2). All SMNs
in patients who did not receive a transplant occurred after cessation
of maintenance therapy. None of the patients with Down syndrome
developed an SMN. Sixteen of the 20 SMNs were AML (n  8) or
MDS (n  8), all but 2 of which occurred within 5.5 years from
diagnosis (median, 3.7 years). One of these AMLs occurred after
SC transplantation. The last 4 patients included a primitive neuroec-
todermal CNS tumor, an oral carcinoma, and 2 post-SC transplanta-
tion cancers (a posttransplantation, lymphoproliferative disease
and a papillary thyroid cancer). The 12-year cumulative risk of
developing an SMN (pSMN12y) was 1.6% plus or minus 0.4%.
Thirteen of the 16 patients with t-AML/MDS received a SCT.
Twelve of the 20 patients died within 21 months from diagnosis of
their SMN with a median time to death of 8.8 months and a
projected survival fraction of 0.39 plus or minus 011 (Table 2).
The projected risk of SMN among the patients who did not
receive a transplant was significantly related to the risk group and
was 2.4% ( 0.7%) for SR-ALL, 1.2% ( 0.7%) for IR-ALL, and
0.3% ( 0.3%) for higher risk ALL patients (P  .007; Figure 2).
Of the 16 SMNs (15 t-AML/MDS) that occurred among the
SR/IR patients, 10 patients had an aberrant karyotype at the time of
ALL diagnosis of which 8 were high-hyperdiploid compared with
301 high-hyperdiploid cases among the 684 SR/IR patients with an
aberrant karyotype who did not develop an SMN (P  .03). This
reaches borderline significance if all successful karyotypes are
included as the denominator (P  .07). Among all 562 SR-ALL
patients, the 161 patients with a high-hyperdiploid karyotype had a
4.8% ( 1.8%) risk of developing an SMN compared with a
1.5% ( 0.6%) risk for the remaining 401 SR patients (P  .02).
No other subsets of genetic aberrations were significantly related to
the risk of developing an SMN.
In all 16 cases of t-AML/MDS a karyotype was available and
showed chromosomal aberrations in all, including one 11q23-
aberration, monosomy 7 (n  7), 7q deletion (n  2), or chromo-
some 5 deletions or translocations (n  5; Table 2). Cytogenetic
aberrations involving chromosomes 5 or 7 occurred in 11 of
15 patients with t-AML/MDS who did not receive a transplant. The
9 -7/7q- t-AML/MDS cases occurred among patients with high-
hyperdiploidy (n  4), t(12;21)(p13;q22) (n  1), or a normal/
missing (n  4) karyotype at diagnosis of ALL. The projected
survival of the 9 -7/7q- t-AML/MDS did not differ significantly
from that of the remaining 11 SMNs (Table 2).
The cumulative risk of developing an SMN was 1.7% ( 0.4%)
for the 1316 patients who were in CR1 when they initiated
MTX/6MP maintenance therapy compared with 0% for the 169 pa-
tients in CR1 at the start of LSA2L2 maintenance therapy.
To analyze the effect of MTX/6MP maintenance therapy on the
risk of SMN, the 1562 patients who did not receive a SCT in CR1
were grouped according to whether they received MTX/6MP
maintenance therapy and its duration in weeks. In backward,
multivariate Cox regression analysis of the SR/IR/HR-ALL pa-
tients who had received MTX/6MP maintenance therapy only the
duration of oral MTX/6MP maintenance therapy in weeks (regres-
sion coefficient, 0.02; P  .04) was related to an increased risk of
an SMN, whereas neither sex, age, and white blood cell count at
diagnosis came out statistically significant. If the analysis included
the presence of a high-hyperdiploid karyotype, only the duration of
MTX/6MP maintenance therapy (regression coefficient, 0.02;
P  .05) and presence of high-hyperdiploidy (P  .07) were
related to an increased risk of an SMN (overall P value of the Cox
model, .02). Finally, inclusion of the VHR patients, most of whom
only received LSA2L2 maintenance therapy, yielded the same
coefficients for the duration of MTX/6MP maintenance therapy
(regression coefficient, 0.02; P  .02) and presence of high-
hyperdiploidy (P  .07; overall P value of the Cox model, .003).
Within the individual SR-, IR-, and HR-ALL risk groups, the
patients who did or did not develop SMN did not differ signifi-
cantly in their actual duration of MTX/6MP maintenance therapy
(P  .2 in all comparisons).
With the limitation that data on MTX and 6MP doses, erythro-
cyte metabolite levels, or blood counts were only available for the
545 patients who participated in the randomized NOPHO ALL-92
maintenance therapy study or developed an SMN (Figure 1), the
patients who developed an SMN did not differ significantly from
the remaining population with respect to their doses of 6MP
(median, 62.4; n  16 vs 59.4 mg/m2 l n  526; P  .18) or MTX
(median, 16.6; n  16 vs 15.3 mg/m2; n  526; P  .21), their
erythrocyte MTX levels (median, 4.9; n  8 vs 5.6 nmol/mmol
hemoglobin [Hb]; n  514; P  .17), their erythrocyte 6TGN
levels (median, 297 vs 170 nmol/mmol Hb; P  .11), or their
average leukocyte (median: 3.4; n  17 vs 3.3  109/L; n  527;
P  .35) or absolute neutrophil counts (median, 2.1; n  17 vs
2.0  109/L; n  529; P  .91). In contrast, the patients who
developed an SMN had significantly lower TPMT activity than did
the remaining patients (median, 12.1 vs 18.1 IU/mL; P  .02;
Figure 3). The patients who developed an SMN received 10% to
15% higher 6MP doses than those that did not develop an SMN,
and this was the case both among patients classified as TPMT low
activity (median, 55.5; n  3 vs 50.3 mg/m2; n  57; P  .31) and
those classified as TPMT wild-type (median, 69.7; n  9 vs
60.4 mg/m2; n  418; P  .03). The patients with lower TPMT
activity tended to be diagnosed with t-AML/MDS earlier than
patients with higher TPMT activity, but this tendency did not reach
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Figure 2. Cumulative risk of a second malignant neoplasm (SMN) by risk group
for patients who did not receive a transplant in first remission. Standard risk
(SR) was 2.4% 0.7%, intermediate risk (IR) was 1.2% 0.7%, and higher risk (HR)
was 0.3% 0.3% (P  .007). ALL indicates acute lymphoblastic leukemia.
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statistical significance in Spearman correlation analysis (rS  0.67,
P  .07). Four of the 76 patients classified as TPMT low activity
developed an SMN (pSMN12y  6%  3%), compared with 9 of
533 classified as TPMT wild-type patients (pSMN12y  2%  1%;
P  .06).
The overall risk of SMN in the randomized NOPHO ALL-92
maintenance therapy study did not differ between the 2 treatment
arms (4 cases among 269 patients in each arm) and did not differ
from that of 1024 patients who did not receive a transplant who did
not participate in the study (P  .9).
Discussion
Today, the most effective treatment protocols for children with
ALL result in cure rates of 80% to 85%.30,31 In this perspective the
life-threatening complications of antileukemic therapy such as
therapy-related SMN increase their relative effect on the overall
survival. Although the risk of SMN within the first 15 years from
diagnosis is only a few percent in most protocols,1,3-5,13,32,33 subsets
of patients with significantly higher risk have been identified.
These subsets include patients exposed to topoisomerase II inhibi-
tors or alkylating agents, in which the genotoxicity and relation to
malignant transformation is well established.5,34 Furthermore, after
CNS irradiation the cumulative risk of head and neck secondary
neoplasms and CNS tumors, including meningiomas, may be well
above 10% at 25 to 30 years from diagnosis of ALL.1,35 Finally,
several drugs have been suggested to modify the risk of SMNs by
interference with DNA repair or by promoting the growth of a
malignant clone. Such agents include L-asparaginase,36 granulocyte
colony-stimulating factor,37 and thiopurines.7,8,38
The present population-based, retrospective study indicates that
maintenance therapy, and especially 6MP pharmacotherapy, influ-
enced the development of SMNs. This conclusion is based on
several lines of evidence. First, the strongest indication that 6MP
influenced the risk of the SMN is the known DNA-damaging effect
of 6MP39-41 and the correlation of the risk of t-AML/MDS to
(1) longer duration of 6MP/MTX maintenance therapy, (2) low
TPMT activity, (3) higher doses of 6MP for TPMT wild-type
patients, and (4) higher 6TGN levels (although nonsignificant).
During oral 6MP therapy 1:103 to 1:104 DNA nucleotides in
leukocytes have been shown to be substituted with 6TGN (DNA-
6TGN),42,43 but at present it is unknown whether the risk of
t-AML/MDS is related to the individual leukocyte DNA-6TGN
levels. Second, none of the patients on NOPHO ALL-92 received
epipodophyllotoxins, which are known to be leukemogenic, at least
in part because of inhibition of topoisomerase II.34,44 Third,
although all patients received anthracyclines during induction
therapy and delayed intensification, the total dose for SR-ALL
patients was only 120 mg/m2. However, malignant clones may
arise a few months after anthracyclines have been administered,
and the subsequent therapy may then have modified the risk of
whether it develops into overt t-AML/MDS,45 and anthracycline
therapy during induction could thus have been a contributing factor
for the development of t-AML/MDS in the present cohort. Fourth,
only the patients with IR-ALL, HR-ALL, and VHR-ALL received
an alkylating agent (3.0-6.6 g/m2 of cyclophosphamide), and none
of the SMNs occurred among the CNS-irradiated patients who did
not receive a transplant. Finally, oral low-dose MTX has rarely
been reported to induce secondary MDS/AML.46 However, HD-
MTX could have been a contributing factor through its inhibition of
purine de novo synthesis and enhancement of DNA-6TGN incorpo-
ration during the concurrently administered 6MP.47,48 Accordingly,
patients with low TPMT activity are more prone to develop severe
myelotoxicity after HD-MTX with concurrently administered
6MP.49
As a result of a common genetic polymorphism, approximately
90% of whites are homozygous for high TPMT activity (TPMT
wild-type), 5% to 10% are heterozygous and express intermediate
TPMT activity, and 1:300 are TPMT deficient.11 Levels of TPMT
activity in red blood cells, lymphocytes, and leukemic blasts are
generally closely correlated, although TPMT gene copy number
changes may modify the TPMT phenotype of the leukemic cells.50
TPMT methylates 6MP and other 6MP metabolites such as
6-thioinosine 5	-monophosphate, producing 6-methyl-mercaptopu-
rine and 6-methyl-thioinosine 5	-monophosphate (MeTIMP), re-
spectively.11 MeTIMP is a strong inhibitor of purine de novo
synthesis,11 and MeTIMP levels increase with higher doses of
6MP,12 which may explain the positive correlation between the
dose of 6MP and the risk of SMN among the TPMT wild-type
patients in the present study, because inhibition of purine de novo
synthesis could have enhanced DNA-6TGN incorporation.
Reduced TPMT activity increases the availability of 6MP for
6TGN formation, resulting in higher E-6TGN, increased myelotox-
icity, and a higher cure rate.16,21,51 Because (1) only the 2 most
common low-activity polymorphism were analyzed in the present
cohort, (2) the concordance between TPMT genotype and pheno-
type is incomplete, and (3) erythrocyte TPMT activity may
fluctuate during therapy because of variation in the life span of red
blood cell,52 it remains to be explored whether TPMT genotyping
or phenotyping is superior in prediction of the risk of SMNs. Since
2001, determination of TPMT genotype/phenotype has been man-
datory in NOPHO protocols, and during the initial maintenance
therapy 6MP dose is reduced to 50 mg/m2 for TPMT heterozygous
patients. With longer follow-up it will be explored whether this
approach has reduced the risk of SMNs for such patients without
increasing their low relapse rate.21
In support of the present findings, St Jude Children’s Research
Hospital has previously reported that the interval between the
diagnosis of ALL and of t-AML/MDS was correlated with TPMT
activity.38 In contrast, the German Berlin-Frankfurt-Mu¨nster (BFM)
study group failed to show a significant relation between low-
activity TPMT genotypes and the risk of SMNs.53 However,
(1) only genotyping and not phenotyping was used in the BFM
study; (2) the backbone maintenance therapy dose of 6MP was
75 mg/m2 in the NOPHO protocol compared with only 50 mg/m2
in the BFM protocol; (3) the total duration of therapy for the
SR-ALL patients was 27 months in NOPHO ALL-92, whereas
maintenance therapy lasts only approximately 18 months for
SR-patients in BFM protocols54; and (4) the BFM protocol only
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Figure 3. Red blood cell thiopurine methyltransferase activity (TPMT) for
patients who developed a second malignant neoplasm compared with patients
who did not. Nine patients developed a SMN (right) compared with 515 patients who
did not (left). Each dot represents 1 patient (median, 12.1 vs 18.1 IU/mL; P  .02).
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give 6MP 25 mg/m2 concurrent with HD-MTX (so-called protocol
M), whereas the NOPHO ALL-92 protocol prescribed HD-MTX
(5 g/m2) 5 times together with concurrent 6MP at 75 mg/m2 during
maintenance therapy, which could have increased 6MP-induced
DNA damage.49,55
Although the pattern of second cancers may change with longer
follow-up, the high relative frequency of t-AML/MDS and their
genetic aberrations in the present study is different from many
previous reports, in which solid tumors were relatively more
common and t-AML/MDS frequently harbored 11q23-aberrations
because of more extensive exposure to topoisomerase II inhibitors
such as epipodophyllotoxins and anthracyclines.34,44,54 Further-
more, t-AML/MDS with deletions of all or part of chromosomes
5 and 7 have previously been linked to exposures to alkylating
agents or radiation therapy.5 Note that only one 11q23-rearranged
case was found in the present cohort [a del(11q23)], whereas
14 cases had chromosome 5 or 7 aberrations. A linkage between
high-hyperdiploid ALL and SMN, including t-AML/MDS with

7/7q-, has not previously been reported, but thiopurine therapy
has been linked to t-AML/MDS with monosomy 7 in patients with
benign disorders.41,56 It is uncertain to what extent the ALL cases
with missing or normal karyotypes in reality had a high-
hyperdiploid clone, but it is well known that conventional chromo-
some analysis may fail to identify high-hyperdiploidy because of
poor in vitro growth of leukemic cells in this ALL subset.23
Because both high-hyperdiploidy and monosomy 7 represent
mitotic nondisjunction, the linkage could represent an individual
propensity for such mitotic errors similar to that identified in
mothers of children with Down syndrome.57
Partly explained by pharmacogenetic polymorphisms, children
with ALL vary significantly in their drug disposition and treatment
response,58 and some, although not all, studies have linked
excessive risks of the development of SMN to specific predispos-
ing genetic polymorphisms such as low-activity glutathione S-
transferase, methylenetetrahydrofolate reductase, NAD(P)H:
quinone oxidoreductase 1, or TPMT polymorphisms.7,8,38,59-64
However, little is known about how to modify therapy to counteract
such genetic predisposition. If the linkage of t-AML/MDS with
high-hyperdiploidy, TPMT low activity, and 6MP treatment inten-
sity is confirmed by others, studies are needed to explore whether
individualized 6MP dose adjustments can reduce their risk of this
sequelae to antileukemic therapy without increasing their rate of
relapse.
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